{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:53:46Z","timestamp":1790398426013,"version":"4.1.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Fentanyl has exacerbated the opioid use disorder (OUD) and opioid overdose epidemic. Data on the effectiveness of medications for OUD among patients using fentanyl are limited.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the effectiveness of sublingual or extended-release injection formulations of buprenorphine for the treatment of OUD among patients with and without fentanyl use.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Post hoc analysis of a 24-week, randomized, double-blind clinical trial conducted at 35 outpatient sites in the US from December 2015 to November 2016 of sublingual buprenorphine-naloxone vs extended-release subcutaneous injection buprenorphine (CAM2038) for patients with OUD subgrouped by presence vs absence of fentanyl or norfentanyl in urine at baseline. Study visits with urine testing occurred weekly for 12 weeks, then 6 times between weeks 13 and 24. Data were analyzed on an intention-to-treat basis from March 2022 to August 2023.<\/jats:p><\/jats:sec>Intervention<\/jats:title>Weekly and monthly subcutaneous buprenorphine vs daily sublingual buprenorphine-naloxone.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Retention in treatment, percentage of urine samples negative for any opioids (missing values imputed as positive), percentage of urine samples negative for fentanyl or norfentanyl (missing values not imputed), and scores on opiate withdrawal scales and visual analog craving scales.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 428 participants, 123 (subcutaneous buprenorphine, n\u2009=\u200964; sublingual buprenorphine-naloxone, n\u2009=\u200959; mean [SD] age, 39.1 [10.8] years; 75 men [61.0%]) had evidence of baseline fentanyl use and 305 (subcutaneous buprenorphine, n\u2009=\u2009149; buprenorphine-naloxone, n\u2009=\u2009156; mean [SD] age, 38.1 [11.1] years; 188 men [61.6%]) did not have evidence of baseline fentanyl use. Study completion was similar between the fentanyl-positive (60.2% [74 of 123]) and fentanyl-negative (56.7% [173 of 305]) subgroups. The mean percentage of urine samples negative for any opioid were 28.5% among those receiving subcutaneous buprenorphine and 18.8% among those receiving buprenorphine-naloxone in the fentanyl-positive subgroup (difference, 9.6%; 95% CI, \u22123.0% to 22.3%) and 36.7% among those receiving subcutaneous buprenorphine and 30.6% among those receiving buprenorphine-naloxone in the fentanyl-negative subgroup (difference, 6.1%; 95% CI, \u22121.9% to 14.1%), with significant main associations of baseline fentanyl status and treatment group. In the fentanyl-positive subgroup, the mean percentage of urine samples negative for fentanyl during the study was 74.6% among those receiving subcutaneous buprenorphine vs 61.9% among those receiving sublingual buprenorphine-naloxone (difference, 12.7%; 95% CI, 9.6%-15.9%). Opioid withdrawal and craving scores decreased rapidly after treatment initiation across all groups.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this post hoc analysis of a randomized clinical trial of sublingual vs extended-release injection buprenorphine for OUD, buprenorphine appeared to be effective among patients with baseline fentanyl use. Patients with fentanyl use had fewer opioid-negative urine samples during the trial compared with the fentanyl-negative subgroup. These findings suggest that the subcutaneous buprenorphine formulation may be more effective at reducing fentanyl use.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT02651584<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.17377","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T15:02:25Z","timestamp":1719327745000},"page":"e2417377","source":"Crossref","is-referenced-by-count":26,"title":["Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use"],"prefix":"10.1001","volume":"7","author":[{"given":"Edward V.","family":"Nunes","sequence":"first","affiliation":[{"name":"Division on Substance Use Disorders, New York State Psychiatric Institute, New York"},{"name":"Columbia University Irving Medical Center Department of Psychiatry, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra D.","family":"Comer","sequence":"additional","affiliation":[{"name":"Division on Substance Use Disorders, New York State Psychiatric Institute, New York"},{"name":"Columbia University Irving Medical Center Department of Psychiatry, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R.","family":"Lofwall","sequence":"additional","affiliation":[{"name":"Department of Behavioral Science and Center on Drug and Alcohol Research, University of Kentucky, Lexington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Department of Behavioral Science and Center on Drug and Alcohol Research, University of Kentucky, Lexington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Peterson","sequence":"additional","affiliation":[{"name":"Camurus AB, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Tiberg","sequence":"additional","affiliation":[{"name":"Camurus AB, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hjelmstrom","sequence":"additional","affiliation":[{"name":"Uppsala Monitoring Centre, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie R.","family":"Budilovsky-Kelley","sequence":"additional","affiliation":[{"name":"Medical Affairs, Braeburn Inc, Plymouth Meeting, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"issue":"4","key":"zoi240572r2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1001\/jama.2022.23563","article-title":"Fentanyl drives startling increases in adolescent overdose deaths.","volume":"329","author":"Kuehn","year":"2023","journal-title":"JAMA"},{"issue":"43","key":"zoi240572r3","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.15585\/mmwr.mm6643e1","article-title":"Deaths involving fentanyl, fentanyl analogs, and U-47700\u20140 states, July\u2013December 2016.","volume":"66","author":"O\u2019Donnell","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"zoi240572r5","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/add.v114.5","article-title":"Illicit fentanyls in the opioid street market: desired or imposed?","volume":"114","author":"Mars","year":"2019","journal-title":"Addiction"},{"issue":"7","key":"zoi240572r6","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1056\/NEJMp1615145","article-title":"Addressing the fentanyl threat to public health.","volume":"376","author":"Frank","year":"2017","journal-title":"N Engl J Med"},{"key":"zoi240572r7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neubiorev.2018.12.005","article-title":"Fentanyl: receptor pharmacology, abuse potential, and implications for treatment.","volume":"106","author":"Comer","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"issue":"11","key":"zoi240572r8","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s12264-022-00872-3","article-title":"Unique pharmacology, brain dysfunction, and therapeutic advancements for fentanyl misuse and abuse.","volume":"38","author":"Han","year":"2022","journal-title":"Neurosci Bull"},{"issue":"7","key":"zoi240572r9","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/bph.v180.7","article-title":"The anomalous pharmacology of fentanyl.","volume":"180","author":"Kelly","year":"2023","journal-title":"Br J Pharmacol"},{"issue":"77","key":"zoi240572r10","first-page":"20039","article-title":"Control of a chemical precursor used in the illicit manufacture of fentanyl as a List I chemical: interim rule with request for comments.","volume":"72","author":"Drug Enforcement Administration (DEA), U.S. Department of Justice","year":"2007","journal-title":"Fed Regist"},{"issue":"9","key":"zoi240572r11","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/add.v114.9","article-title":"How the complex pharmacology of the fentanyls contributes to their lethality.","volume":"114","author":"Gill","year":"2019","journal-title":"Addiction"},{"key":"zoi240572r12","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.12f01371","author":"Keary","year":"2012","journal-title":"Prim Care Companion CNS Disord"},{"issue":"2","key":"zoi240572r13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: review of the evidence and future directions.","volume":"23","author":"Connery","year":"2015","journal-title":"Harv Rev Psychiatry"},{"issue":"4","key":"zoi240572r14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/ADM.0000000000000486","article-title":"Impact of fentanyl use on buprenorphine treatment retention and opioid abstinence.","volume":"13","author":"Wakeman","year":"2019","journal-title":"J Addict Med"},{"issue":"2","key":"zoi240572r15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/wps.v20.2","article-title":"The epidemic of fentanyl misuse and overdoses: challenges and strategies.","volume":"20","author":"Volkow","year":"2021","journal-title":"World Psychiatry"},{"issue":"6","key":"zoi240572r16","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial.","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"2","key":"zoi240572r17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/10543400802609797","article-title":"MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets.","volume":"19","author":"Siddiqui","year":"2009","journal-title":"J Biopharm Stat"},{"key":"zoi240572r18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.drugpo.2017.05.023","article-title":"Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: a mixed methods study.","volume":"46","author":"Carroll","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"1","key":"zoi240572r19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/add.2014.109.issue-1","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial.","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"issue":"10118","key":"zoi240572r20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"10173","key":"zoi240572r21","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"key":"zoi240572r22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.addbeh.2015.02.002","article-title":"Web-based treatment for substance use disorders: differential effects by primary substance.","volume":"45","author":"Cochran","year":"2015","journal-title":"Addict Behav"},{"key":"zoi240572r23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jsat.2017.11.005","article-title":"Low-threshold extended-release naltrexone for high utilizers of public services with severe alcohol use disorder: a pilot study.","volume":"85","author":"Smith-Bernardin","year":"2018","journal-title":"J Subst Abuse Treat"},{"issue":"7","key":"zoi240572r24","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1176\/appi.ajp.2020.20060816","article-title":"Sublingual buprenorphine-naloxone compared with injection naltrexone for opioid use disorder: potential utility of patient characteristics in guiding choice of treatment.","volume":"178","author":"Nunes","year":"2021","journal-title":"Am J Psychiatry"},{"issue":"5","key":"zoi240572r25","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/ajad.v30.5","article-title":"Open-label trial of a single-day induction onto buprenorphine extended-release injection for users of heroin and fentanyl.","volume":"30","author":"Mariani","year":"2021","journal-title":"Am J Addict"},{"issue":"3","key":"zoi240572r26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.6108","article-title":"Incidence of precipitated withdrawal during a multisite emergency department\u2013initiated buprenorphine clinical trial in the era of fentanyl.","volume":"6","author":"D\u2019Onofrio","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi240572r27","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/add.v114.5","article-title":"What should clinicians do as fentanyl replaces heroin?","volume":"114","author":"Bisaga","year":"2019","journal-title":"Addiction"},{"key":"zoi240572r28","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","article-title":"\u201cEverything is not right anymore\u201d: buprenorphine experiences in an era of illicit fentanyl.","volume":"74","author":"Silverstein","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"1","key":"zoi240572r29","doi-asserted-by":"publisher","DOI":"10.1002\/emp2.v4.1","article-title":"Precipitated opioid withdrawal after buprenorphine administration in patients presenting to the emergency department: a case series.","volume":"4","author":"Spadaro","year":"2023","journal-title":"J Am Coll Emerg Physicians Open"},{"issue":"17","key":"zoi240572r30","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1001\/jama.2018.2844","article-title":"Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010-2016.","volume":"319","author":"Jones","year":"2018","journal-title":"JAMA"},{"key":"zoi240572r31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.drugalcdep.2017.04.004","article-title":"Increases in self-reported fentanyl use among a population entering drug treatment: the need for systematic surveillance of illicitly manufactured opioids.","volume":"177","author":"Cicero","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"zoi240572r1","unstructured":"Trends & statistics: drug overdose death rates. National Institute on Drug Abuse. Accessed June 23, 2023. https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates"},{"key":"zoi240572r4","unstructured":"DEA Intelligence Brief. Counterfeit prescription pills containing fentanyls: a global threat: DEA-DCT-DIB-021-16. July 2016. Drug Enforcement Administration Strategic Intelligence Section. Accessed April 24, 2024. https:\/\/www.dea.gov\/sites\/default\/files\/docs\/Counterfeit%2520Prescription%2520Pills.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2820306\/nunes_2024_oi_240572_1721157765.63547.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T17:37:13Z","timestamp":1721756233000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2820306"}},"subtitle":["A Post Hoc Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.17377","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]}}}